

IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/560,250
Filing Date	December 12, 2005
First Named Inventor	Glen NEMEROW
Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket Number	5410-007 NATL

Total Number of Pages in This Submission 14 pages

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Sixty-five (65) References 2. Return-receipt postcard
<div>Remarks</div> <p>The Commissioner is authorized to charge any deficiencies in fees and credit any overpayment of fees to Deposit Account No. 07-1896. A duplicate page is enclosed.</p> <p>Customer No. 29585</p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	DLA Piper Rudnick Gray Cary US LLP, 153 Townsend Street, Suite 800, San Francisco, CA 94107-1957		
Signature			
Printed name	Linda R. Judge, Telephone: 415-836-2586, Facsimile: 415-836-2501		
Date	April 21, 2006	Reg. No.	42,702

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Mail Stop Amendment			
Signature			
Typed or printed name	Kathleen A. Farrell	Date	April 21, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

The PTO did not receive the following listed item(s) FOR 5

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of

2

Complete if Known

Application Number	10/560,250
Filing Date	December 12, 2005
First Named Inventor	Glen NEMEROW
Art Unit	1645
Examiner Name	To Be Assigned
Attorney Docket Number	5410-007 NATL

Mail Stop Amendment

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. § 1.56(a) and 37 C.F.R. § 1.97, Applicant(s) hereby make of record the references listed on the accompanying form, SB/08A and/or SB/08b for consideration by the Examiner in connection with the examination of the above-identified patent application.

This Information Disclosure Statement:

- (a) accompanies a new patent application submitted herewith.
- (b) ☒ **is filed within three (3) months of the Filing Date or before the mailing date of a First Office Action on the merits; OR**
- (c) is filed after the first Office Action and more than three months after the application's filing date or PCT national stage date of entry filing but, as far as is known to the undersigned prior to the mailing date of either a final rejection or a notice of allowance, and is accompanied by either the fee (\$180) set forth in 37 CFR § 1.17(p) or a certification as specified in 37 CFR § 1.97(e), as checked below **OR**
- (d) is filed after the mailing date of either a final rejection or a notice of allowance, and the issue fee has not been paid, and is accompanied by the requisite petition fee (\$130) set forth in 37 CFR § 1.17(l)(1) and a certification as specified in 37 CFR § 1.97(e), as checked below.
This document is to be considered as a petition requesting consideration of the information disclosure statement.

As required under § 1.97(e), Applicants, through the undersigned, hereby state either that [check the appropriate space]:

- (e) Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Information Disclosure Statement; or
- (f) No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Each item of information listed in the attached FORM PTO/SB/08a and/or SB/08b may be material to the examination of the above-identified application and is, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR 1.56, 1.97 and 1.98. The Examiner is requested to make these items of official record in this application.

Pursuant to notice entitled "Information Disclosure Statements May Be Filed Without Copies Of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003," *Off. Gaz. Pat. Office* 55 (August 5, 2003), no copies of U.S. Patents and U.S. Published Patent Applications are being supplied with this Information Disclosure Statement.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/560,250
		Filing Date	December 12, 2005
		First Named Inventor	Glen NEMEROW
		Art Unit	1645
		Examiner Name	To Be Assigned
(Use as many sheets as necessary)		Attorney Docket Number	5410-007 NATL
Sheet	2	of	2

This Information Disclosure Statement under 37 CFR 1.56, 1.97 and 1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these items constitutes prior art.


If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this submission as a conditional petition for acceptance of the information disclosure statement.

The Commissioner is authorized to charge any deficiencies and credit any overpayment of fees to our Deposit Account No. 07-1896.

Respectfully submitted,


Date: April 21, 2006

DLA Piper Rudnick Gray Cary US LLP


 By: Linda R. Judge
 Reg. No. 42,702
 Attorneys for Applicant(s)
 153 Townsend Street, Suite 800
 San Francisco, CA 94107-1957
 Tel. (415) 836-2500
 Fax. (415) 836-2501

Customer Number or Bar Code Label	29585 (Insert Customer No. or Attach bar code label here)
-----------------------------------	--

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service in an envelope, addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>4/21/06</u> Date	<u>Kathleen Farrell</u> Kathleen Farrell



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/560,250		
		Filing Date	December 12, 2005		
		First Named Inventor	Glen NEMEROW		
		Art Unit	1645		
		Examiner Name	To Be Assigned		
Sheet	1	of	10	Attorney Docket Number	5410-007 NATL

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,543,328	08-06-1996	McClelland et al.	
	AB	US-5,731,190	03-24-1998	Wickham et al.	
	AC	US-5,756,086	05-26-1998	McClelland et al.	
	AD	US-5,801,029	09-01-1998	Mccormick et al.	
	AE	US-5,919,676	07-06-1999	Graham et al.	
	AF	US-5,922,576	07-13-1999	He et al.	
	AG	US-5,965,431	10-12-1999	Markl et al.	
	AH	US-5,965,541	10-12-1999	Wickham et al.	
	AI	US-5,994,106	11-30-1999	Kovesdi et al.	
	AJ	US-5,998,205	12/1999	Hallenbeck et al.	
	AK	US-6,057,155	05-02-2000	Wickham et al.	
	AL	US-6,080,569	06-27-2000	Graham et al.	
	AM	US-6,638,762	10-28-2003	Chang et al.	
	AN	US-6,731,190	05-04-2004	Yamashita et al.	
	AO	US-6,156,497	12-05-2000	Kaleko	
	AP	US-5,935,935	08-10-1999	Connelly et al.	
	AQ	US20020137213	09-26-2002	Hallenbeck et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	AR	WO2000US42208	05-31-2001	Milnes et al.		
	AS	WO0130843	05-03-2001	Barbas et al.		
	AT	WO0183729	08-11-2001	Nemerow et al.		
	AU	WO0192299	0612--2001	Jakubczak et al.		
	AV	WO02067861	09-06-2002	Ennist et al.		
	AW	WO03062400	07-31-2003	Kaleko et al.		
	AX	WO0040558	07-13-2000	Randad et al.		
	AY	WO9500655	01-05-1995	Graham et al.		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/560,250
				Filing Date	December 12, 2005
				First Named Inventor	Glen NEMEROW
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	4	of	10	Attorney Docket Number	5410-007 NATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	BL	ADRIAN et al., "Cryo-electron microscopy of viruses" <i>Nature</i> , Vol. 308, pp. 32-36, March 1, 1984, Nature Publishing Group, (1984).	
	BM	ARNBERG et al., "Fiber genes of adenoviruses with tropism for the eye and the genital tract" <i>Virology</i> , Vol. 227, pp. 239-244 (1997)	
	BN	ARNBERG et al., "Adenovirus Type 37 Uses Sialic Acid as a Cellular Receptor" <i>Journal of Virology</i> , Vol. 72, No. 1, pp. 42-48, American Society of Microbiology (2000).	
	BO	ATSCHUL et al., "Basic Local Alignment Search Tool", <i>Journal Molecular Biology</i> , Vol. 215:pp. 403-410 Academic Press Limited, (1990).	
	BP	BAI et al., "Mutations That Alter an Arg-Gly-Asp (RGD) Sequence in the Adenovirus Type 2 Penton Base Protein Abolish Its Cell-Rounding Activity and Delay Virus Reproduction in Flat Cells", <i>Journal of Virology</i> Vol. 67, No. 9, pp. 5198-5205, American Society of Microbiology (1993).	
	BQ	BELOUSOVA et al., "Modulation of Adenovirus Vector Tropism via Incorporation of Polypeptide Ligands into the Fiber Protein", <i>Journal of Virology</i> , Vol. 76, No. 17, pp. 8621-8631. American Society of Microbiology (2002).	
	BR	BERGELSON et al., "Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5", <i>Science</i> , Vol. 275:pp. 1320-1323 (1997)	
	BS	BETT et al., "An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3" <i>Proc. Natl. Acad. Sci USA</i> 91:8802-8806 (1994)	
	BT	BEWLEY et al., "Structural Analysis of the Mechanism of Adenovirus Binding to Its Human Cellular Receptor, CAR", <i>Science</i> Vol. 286, pp. 1579-1583, (1999).	
	BU	CARIILLO et al., "The Multiple Sequence Alignment Problem in Biology", <i>SIAM J. Applied Math</i> , Vol. 48, No. 5, pp. 1073-1082 (1988).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/560,250
				Filing Date	December 12, 2005
				First Named Inventor	Glen NEMEROW
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	5	of	10	Attorney Docket Number	5410-007 NATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	BV	CHAPPELL et al, "Crystal structure of reovirus attachment protein 61 reveals evolutionary relationship to adenovirus fiber" European Molecular Biology Organization, Vol. 21, pp. 1-11, (2002).	
	BW	CHIU et al, "Structural Analysis of a Fiber-Pseudotyped Adenovirus with Ocular Tropism Suggests Differential Modes of Cell Receptor Interactions" <i>Journal of Virology</i> , Vol. 75, No. 11, pp. 5375-5380, American Society for Microbiology (2001).	
	BX	CHIU et al, "Structure of Adenovirus Complexed with Its Internalization Receptor, $\alpha_5\beta_5$ Integrin", <i>Journal of Virology</i> , Vol. 75, pp. 6759-6768, American Society for Microbiology (1999).	
	BY	CHOI et al, "A Generic Intron Increases Gene Expression in Transgenic Mice", <i>Molecular and Cellular Biology</i> , Vol. 11, pp. 3070-3074, American Society for Microbiology (1991).	
	BZ	CHROBOCZEK et al, "Adenovirus Fiber" <i>Current Topics in Microbiology and Immunology</i> , Vol. 199, pp. 163-200 (1995).	
	CA	COHEN et al, "The coxackievirus and adenovirus receptor is a transmembrane component of the tight junction" <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 98, pp. 15191-15196, (2001).	
	CB	DEVEREUX et al. "A comprehensive set of sequence analysis programs for the VAX" <i>Nucleic Acids Research</i> , Vol. 12, No. 1, pp. 387-395, IRL Press Limited (1984).	
	CC	DUBRIDGE et al, "Analysis of Mutation in Human Cells by Using an Epstein-Barr Virus Shuttle System" <i>Molecular and Cellular Biology</i> , Vol. 7, pp. 379-387, American Society of Microbiology (1987).	
	CD	EINFELD et al, "Reducing the Native Tropism of Adenovirus Vectors Requires Removal of both CAR and Integrin Interactions, <i>Journal of Virology</i> , Vol. 75, pp. 11284-11291, American Society for Microbiology (2001).	
	CE	GORZIGLIA et al, "Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy", <i>Journal of Virology</i> , Vol. 70, No. 6, pp. 4173-4178, American Society for Microbiology (1996).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/560,250
				Filing Date	December 12, 2005
				First Named Inventor	Glen NEMEROW
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	6	of	10	Attorney Docket Number	5410-007 NATL

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	CF	GRAHAM et al. "Characteristics of a human cell line transformed by DNA from human adenovirus type 5" <i>Journal of General Virology</i> , Vol. 36, pp. 59-72 (1977)/
	CG	GREEN et al, "Evidence for a repeating cross- β sheet structure in the adenovirus fibre", <i>The EMBO Journal</i> , Vol. 2, No. 8, pp. 1357-1365, IRL Press Limited (1983).
	CH	GRIBSKOV et al., "Sigma factors from <i>E. coli</i> , <i>B. subtilis</i> , phage SP01, and phage T4 are homologous proteins" <i>Nucleic Acids Research</i> , Vol. 14, No. 16, pp. 6745-6763, IRL Press Limited (1986).
	CI	HAECKER et al, "In Vivo Expression of Full-Length Human Dystrophin from Adenoviral Vectors Deleted of All Viral Genes", <i>Human Gene Therapy</i> , Vol. 7, pp. 1907-1914, Mary Ann Liebert, Inc. (1996)
	CJ	HAVENGA et al, "Exploiting the Natural Diversity in Adenovirus Tropism for Therapy and Prevention of Disease", <i>Journal of Virology</i> , Vol. 76, No. 9, pp. 4612-4620, American Society for Microbiology (2002).
	CK	HAWIGER et al, "Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions In Vivo", <i>J. Exp. Med.</i> , Vol. 194, No. 6, pp. 769-779, The Rockefeller University Press (2001).
	CL	HE et al. "Interaction of coxsackievirus B3 with the full length coxsackivirus-adenovirus receptor", <i>Nature Structural Biology</i> , Vol. 8, No. 10, pp. 874-878, Nature Publishing Group (2001).
	CM	HE et al, "A simplified system for generating recombinant adenoviruses", <i>Proc. Natl. Acad. Sci.</i> , Vol. 95, pp. 2509-2514, The National Academy of Sciences (1998).
	CN	HORTON et al, "Adenovirus E3 14.7K Protein Functions in the Absence of Other Adenovirus Proteins To Protect Transfected Cells from Tumor Necrosis Factor Cytolysis" <i>Journal of Virology</i> , Vol. 65, No. 5, pp. 2629-2639, American Society for Microbiology (1991).
	CO	Huang et al, "A Single Amino Acid in the Adenovirus Type 37 Fiber Confers Binding to Human Conjunctival Cells" <i>Journal of Virology</i> , Vol. 73, No. 4, pp. 2798-2802, American Society for Microbiology (1999).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, US. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/560,250
				Filing Date	December 12, 2005
				First Named Inventor	Glen NEMEROW
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	7	of	10	Attorney Docket Number	5410-007 NATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	CP	KLEIN et al., "Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR", <i>Gene Therapy</i> , Vol. 7, pp. 458-463, Macmillan Publishers (2000).	
	CQ	LU, "TOP: a new method for protein structure comparisons and similarity searches", <i>Journal of Applied Crystallography</i> , Vol. 33, pp. 176-183, International Union of Crystallography (2000).	
	CR	MARTIN-PADURA et al., "Junctional Adhesion Molecule, a Novel Member of the Immunoglobulin Superfamily That Distributes at Intercellular Junctions and Modulates Monocyte Junctions", <i>The Journal of Cell Biology</i> , Vol. 142, No. 1, pp. 117-127 The Rockefeller University Press (1998).	
	CS	MORSY et al., "Expanded-capacity adenoviral vectors – the helper-dependent vectors", <i>Molecular Medicine Today</i> , pp. 18-24, Elsevier Science, (Jan. 1999).	
	CT	NEEDLEMAN et al., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins", <i>Journal of Molecular Biology</i> , Vol 48, pp.443-453 (1970)	
	CU	NEMEROW, "Cell Receptors Involved in Adenovirus Entry", <i>Virology</i> , Vol. 274, pp. 1-4, Academic Press (2000).	
	CV	PALMITER et al., "Germ-Line Transformation of Mice" <i>Annual Review Genetics</i> , Vol. 20, pp. 465-499 (1986).	
	CW	PEARSON et al., "Improved tools for biological sequence comparison, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 85, pp. 2444-2448 (1988).	
	CX	PETITCLERC et al., "The effect of various introns and transcription terminators on the efficiency of expression vectors in various cultured cell lines and in the mammary gland of transgenic mice", <i>Journal of Biotechnology</i> , Vol. 40, pp.169-178, Elsevier Science B.V. (1995).	
	CY	PHILIPSON et al., "Virus-Receptor Interaction in an Adenovirus System", <i>Journal of Virology</i> , Vol. 2, pp. 1064-1075, American Society for Microbiology (1968).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/560,250
				Filing Date	December 12, 2005
				First Named Inventor	Glen NEMEROW
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	8	of	10	Attorney Docket Number	5410-007 NATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	CZ	REA et al, "Highly Efficient Transduction of Human Monocyte-Derived Dendritic Cells with Subgroup B Fiber-Modified Adenovirus Vectors Enhances Transgene-Encoded Antigen Presentation to Cytotoxic T Cells", <i>Journal of Immunology</i> , Vol. 166, pp. 5236-5244, The American Association of Immunologists (2001).	
	DA	ROELVINK et al, "Comparative Analysis of Adenovirus Fiber-Cell Interaction: Adenovirus Type 2 (Ad2) and Ad9 Utilize the Same Cellular Fiber Receptor but Use Different Binding Strategies for Attachment", <i>Journal of Virology</i> , Vol. 70, No. 11, pp. 7614-7621, American Society for Microbiology (1996).	
	DB	ROELVINK et al, "The Coxsackievirus-Adenovirus Receptor Protein Can Function as a Cellular Attachment Protein for Adenovirus Serotypes from Subgroups A, C, D, E, and F", <i>Journal of Virology</i> , Vol. 72, No. 10, pp. 7909-7915, American Society for Microbiology (1998).	
	DC	ROELVINK et al., "Identification of a Conserved Receptor-Binding Site on the Fiber Proteins of CAR-Recognizing Adenoviridae", <i>Science</i> , Vol. 286, pp. 1568-1571 (1999).	
	DD	RUIGROK et al., "Structure of Adenovirus Fibre", <i>Journal of Molecular Biology</i> , Vol. 215, pp. 589-596, Academic Press Limited (1990).	
	DE	SANDIG et al., "Optimization of the helper-dependent adenovirus system for production and potency <i>in vivo</i> ", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 97, No. 3, pp. 1002-7, PNAS (2000).	
	DF	SCANLAN et al., "Challenges to the development of antigen-specific breast cancer vaccines", <i>Breast Cancer Research</i> , Vol. 3, pp. 95-98 (2001).	
	DG	SHAH et al., "QVIEW: Software for Rapid Selection of Particles from Digital Electron Micrographs", <i>Journal of Structural Biology</i> , Vol. 123, pp. 17-21, Article No. SB984011, Academic Press (1998).	
	DH	SHAYAKHMETOV et al. "Dependence of Adenovirus Infectivity on Length of the Fiber Shaft Domain", <i>Journal of Virology</i> , Vol. 74, No. 22, pp. 10274-10286, (2000).	
	DI	SHILO et al., "DNA sequences homologous to vertebrate oncogenes are conserved in <i>Drosophila melanogaster</i> " <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 78, No. 11, pp. 6789-6792, Biochemistry (1981).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/560,250		
		Filing Date	December 12, 2005		
		First Named Inventor	Glen NEMEROW		
		Art Unit	1645		
		Examiner Name	To Be Assigned		
Sheet	9	of	10	Attorney Docket Number	5410-007 NATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	DJ	SMITH et al., "Comparison of Biosequences", <i>Advances in Applied Mathematics</i> , Vol. 2, pp. 482-489, Academic Press, Inc. (1981).	
	DK	STEINMAN et al., "Tolerogenic Dendritic Cells" <i>Annual Rev. Immunol.</i> , Vol. 21, pp. 685-711, Annual Reviews (2003).	
	DL	STEVENSON et al., "Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular Receptors via the Fiber Head Domain" <i>Journal of Virology</i> , Vol. 69, No. 5, pp. 2850-2857, American Society for Microbiology (1995).	
	DM	STEWART et al., "Digitally Collected Cryo-Electron Micrographs for Single Particle Reconstruction", <i>Microscopy Research and Technique</i> , Vol. 49, pp. 224-232, Wiley-Liss, Inc. (2000).	
	DN	STEWART et al. "Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization, <i>EMBO Journal</i> , Vol. No. 6, 16, pp. 1189-1198, Oxford University Press (1997).	
	DO	VAN HEEL et al., "A New Generation of the IMAGIC Image Processing System", <i>Journal of Structural Biology</i> , Vol. 116, Article No. 004, pp. 17-24, Academic Press, Inc. (1996).	
	DP	VAN RAAIJ et al. "Dimeric Structure of the Coxsackievirus and Adenovirus Receptor D1 Domain at 1.7 Å Resolution", <i>Structure</i> , Vol. 8, pp. 1147-1155, Elsevier Science Ltd. (2000).	
	DQ	VAN RAAIJ et al., "A triple β -spiral in the adenovirus fibre shaft reveals a new structural motif for a fibrous protein", <i>Nature</i> , Vol. 401, pp. 935-938, Macmillan Magazines Ltd (1999).	
	DR	VON SEGGERN et al., "Complementation of a fibre mutant adenovirus by packaging" <i>Journal of General Virology</i> , Vol. 79, pp. 1461-1468, SGM (1998).	
	DS	VON SEGGERN et al., "A Helper-Independent Adenovirus Vector with E1, E3, and Fiber Deleted: Structure and Infectivity of Fiberless Particles", <i>Journal of Virology</i> , Vol. 73, No. 2, pp. 1601-1608, American Society for Microbiology (1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/560,250
				Filing Date	December 12, 2005
				First Named Inventor	Glen NEMEROW
				Art Unit	1645
				Examiner Name	To Be Assigned
Sheet	10	of	10	Attorney Docket Number	5410-007 NATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	DT	VON SEGGERN et al, "Adenovirus Vector Pseudotyping in Fiber-Expressing Cell Lines: Improved Transduction of Epstein-Barr Virus-Transformed B Cells" <i>Journal of Virology</i> , Vol. 74, No. 1, pp. 354-362, American Society for Microbiology (2000).	
	DU	WICKAM et al., "Integrins $\alpha_3\beta_3$ and $\alpha_3\beta_5$ Promote Adenovirus Internalization but Not Virus Attachment", <i>Cell</i> , Vol. 73, pp. 309-319 Cell Press (1993).	
	DV	WU et al., "A 50-kDa Membrane Protein Mediates Sialic Acid-Independent Binding and Infection of Conjunctival Cells by Adenovirus Type 37", <i>Virology</i> , Vol. 279, pp: 78-89, Academic Press (2001).	
	DW	XIA et al., "Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 Å resolution", <i>Structure</i> , Vol. 2, pp. 1259-1270, Current Biology Ltd. (1994).	
	DX	YU et al., "Cancer vaccines: progress reveals new complexities", <i>Journal of Clinical Investigation</i> , Vol. 110, No. 3, pp.289-94, (2002).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.